TLR4 and type 1 diabetes mellitus: In the present study, both 7.0% w/w and 10.5% w/w FO feeding reversed STZ-induced hepatic inflammation by downregulating LPS/TLR4/MyD88 pathways, which indicated that FO supplementation may act as an anti-inflammatory food in the treatment of type 1 diabetes.